Related Experiment Video
Updated: Apr 25, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective
Takashi Waki1,2, Shinya Watanabe1,2, Takashi Ando1,2
1Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
None:
For pharmacovigilance, the Pharmaceuticals and Medical Devices Agency in Japan has utilized real world data (RWD) from multiple sources, including individual case safety reports, and medical information databases that capture routinely collected data from clinical practice. These RWD have their own characteristics with advantages and disadvantages. In this commentary, we describe current and future direction of post-marketing drug safety assessment in Japan.
More Related Videos
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Clinical Trials: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Product Stability

